Clinical Trial Update: Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 pharmacokinetics and tolerability study of Risperidone ISM in schizophrenia completed; results posted July 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperidone ISM (risperidone)

Snippet

Sponsor: Rovi Pharmaceuticals Laboratories | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2017-07-13